138 related articles for article (PubMed ID: 31570905)
1. A pan-cancer analysis of progression mechanisms and drug sensitivity in cancer cell lines.
Fleck JL; Pavel AB; Cassandras CG
Mol Omics; 2019 Dec; 15(6):399-405. PubMed ID: 31570905
[TBL] [Abstract][Full Text] [Related]
2. Data Mining Approaches for Genomic Biomarker Development: Applications Using Drug Screening Data from the Cancer Genome Project and the Cancer Cell Line Encyclopedia.
Covell DG
PLoS One; 2015; 10(7):e0127433. PubMed ID: 26132924
[TBL] [Abstract][Full Text] [Related]
3. Identification of selective cytotoxic and synthetic lethal drug responses in triple negative breast cancer cells.
Gautam P; Karhinen L; Szwajda A; Jha SK; Yadav B; Aittokallio T; Wennerberg K
Mol Cancer; 2016 May; 15(1):34. PubMed ID: 27165605
[TBL] [Abstract][Full Text] [Related]
4. Integrated pan-cancer gene expression and drug sensitivity analysis reveals SLFN11 mRNA as a solid tumor biomarker predictive of sensitivity to DNA-damaging chemotherapy.
Shee K; Wells JD; Jiang A; Miller TW
PLoS One; 2019; 14(11):e0224267. PubMed ID: 31682620
[TBL] [Abstract][Full Text] [Related]
5. Integrative modeling of multi-omics data to identify cancer drivers and infer patient-specific gene activity.
Pavel AB; Sonkin D; Reddy A
BMC Syst Biol; 2016 Feb; 10():16. PubMed ID: 26864072
[TBL] [Abstract][Full Text] [Related]
6. Genetic load makes cancer cells more sensitive to common drugs: evidence from Cancer Cell Line Encyclopedia.
Pavel AB; Korolev KS
Sci Rep; 2017 May; 7(1):1938. PubMed ID: 28512298
[TBL] [Abstract][Full Text] [Related]
7. The stepwise evolution of the exome during acquisition of docetaxel resistance in breast cancer cells.
Hansen SN; Ehlers NS; Zhu S; Thomsen MB; Nielsen RL; Liu D; Wang G; Hou Y; Zhang X; Xu X; Bolund L; Yang H; Wang J; Moreira J; Ditzel HJ; Brünner N; Schrohl AS; Stenvang J; Gupta R
BMC Genomics; 2016 Jun; 17():442. PubMed ID: 27277198
[TBL] [Abstract][Full Text] [Related]
8. Identifying Candidate Druggable Targets in Canine Cancer Cell Lines Using Whole-Exome Sequencing.
Das S; Idate R; Cronise KE; Gustafson DL; Duval DL
Mol Cancer Ther; 2019 Aug; 18(8):1460-1471. PubMed ID: 31175136
[TBL] [Abstract][Full Text] [Related]
9. Establishment and characterization of cell lines from chromosomal instable colorectal cancer.
Maletzki C; Gock M; Randow M; Klar E; Huehns M; Prall F; Linnebacher M
World J Gastroenterol; 2015 Jan; 21(1):164-76. PubMed ID: 25574089
[TBL] [Abstract][Full Text] [Related]
10. Cancer in silico drug discovery: a systems biology tool for identifying candidate drugs to target specific molecular tumor subtypes.
San Lucas FA; Fowler J; Chang K; Kopetz S; Vilar E; Scheet P
Mol Cancer Ther; 2014 Dec; 13(12):3230-40. PubMed ID: 25349306
[TBL] [Abstract][Full Text] [Related]
11. Changing mutational and adaptive landscapes and the genesis of cancer.
Liggett LA; DeGregori J
Biochim Biophys Acta Rev Cancer; 2017 Apr; 1867(2):84-94. PubMed ID: 28167050
[TBL] [Abstract][Full Text] [Related]
12. Gene expression patterns that predict sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer cell lines and human lung tumors.
Balko JM; Potti A; Saunders C; Stromberg A; Haura EB; Black EP
BMC Genomics; 2006 Nov; 7():289. PubMed ID: 17096850
[TBL] [Abstract][Full Text] [Related]
13. Genomic and transcriptomic analysis of imatinib resistance in gastrointestinal stromal tumors.
Takahashi T; Elzawahry A; Mimaki S; Furukawa E; Nakatsuka R; Nakamura H; Nishigaki T; Serada S; Naka T; Hirota S; Shibata T; Tsuchihara K; Nishida T; Kato M
Genes Chromosomes Cancer; 2017 Apr; 56(4):303-313. PubMed ID: 27997714
[TBL] [Abstract][Full Text] [Related]
14. A pan-cancer analysis of the HER family gene and their association with prognosis, tumor microenvironment, and therapeutic targets.
Yang X; Miao Y; Wang J; Mi D
Life Sci; 2021 May; 273():119307. PubMed ID: 33691171
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer.
Vilquin P; Donini CF; Villedieu M; Grisard E; Corbo L; Bachelot T; Vendrell JA; Cohen PA
Breast Cancer Res; 2015 Jan; 17(1):13. PubMed ID: 25633049
[TBL] [Abstract][Full Text] [Related]
16. A Cell-Based Method for Identification of Chemotherapy Resistance Cancer Genes.
Hellweg R; Mooneyham A; Bazzaro M
Methods Mol Biol; 2019; 1907():83-90. PubMed ID: 30542992
[TBL] [Abstract][Full Text] [Related]
17. RNA Sequencing of the NCI-60: Integration into CellMiner and CellMiner CDB.
Reinhold WC; Varma S; Sunshine M; Elloumi F; Ofori-Atta K; Lee S; Trepel JB; Meltzer PS; Doroshow JH; Pommier Y
Cancer Res; 2019 Jul; 79(13):3514-3524. PubMed ID: 31113817
[TBL] [Abstract][Full Text] [Related]
18. Identification of multiple mechanisms of resistance to vemurafenib in a patient with BRAFV600E-mutated cutaneous melanoma successfully rechallenged after progression.
Romano E; Pradervand S; Paillusson A; Weber J; Harshman K; Muehlethaler K; Speiser D; Peters S; Rimoldi D; Michielin O
Clin Cancer Res; 2013 Oct; 19(20):5749-57. PubMed ID: 23948972
[TBL] [Abstract][Full Text] [Related]
19. Multidrug resistant lncRNA profile in chemotherapeutic sensitive and resistant ovarian cancer cells.
Xu J; Wu J; Fu C; Teng F; Liu S; Dai C; Shen R; Jia X
J Cell Physiol; 2018 Jun; 233(6):5034-5043. PubMed ID: 29219179
[TBL] [Abstract][Full Text] [Related]
20. The Integrative Method Based on the Module-Network for Identifying Driver Genes in Cancer Subtypes.
Lu X; Li X; Liu P; Qian X; Miao Q; Peng S
Molecules; 2018 Jan; 23(2):. PubMed ID: 29364829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
